142 related articles for article (PubMed ID: 26707881)
21. Co-administration of JQ1, a bromodomain-containing protein 4 inhibitor, enhances the antitumor effect of combretastatin A4, a microtubule inhibitor, while attenuating its cardiotoxicity.
Orihara H; Ma M; Nagashima Y; Tochinai R; Sekizawa SI; Kato D; Shinada M; Aoki S; Fujita N; Nakagawa T; Tsuru Y; Tatewaki Y; Mutoh T; Taki Y; Nishimura R; Kuwahara M
Biomed Pharmacother; 2023 Apr; 160():114353. PubMed ID: 36736274
[TBL] [Abstract][Full Text] [Related]
22. RUNX2 expression in thyroid and breast cancer requires the cooperation of three non-redundant enhancers under the control of BRD4 and c-JUN.
Sancisi V; Manzotti G; Gugnoni M; Rossi T; Gandolfi G; Gobbi G; Torricelli F; Catellani F; Faria do Valle I; Remondini D; Castellani G; Ragazzi M; Piana S; Ciarrocchi A
Nucleic Acids Res; 2017 Nov; 45(19):11249-11267. PubMed ID: 28981843
[TBL] [Abstract][Full Text] [Related]
23. Aberrant epigenetic regulation of bromodomain BRD4 in human colon cancer.
Rodriguez RM; Huidobro C; Urdinguio RG; Mangas C; Soldevilla B; Domínguez G; Bonilla F; Fernandez AF; Fraga MF
J Mol Med (Berl); 2012 May; 90(5):587-95. PubMed ID: 22120039
[TBL] [Abstract][Full Text] [Related]
24. Inverse Agonist of Estrogen-Related Receptor γ Enhances Sodium Iodide Symporter Function Through Mitogen-Activated Protein Kinase Signaling in Anaplastic Thyroid Cancer Cells.
Singh TD; Jeong SY; Lee SW; Ha JH; Lee IK; Kim SH; Kim J; Cho SJ; Ahn BC; Lee J; Jeon YH
J Nucl Med; 2015 Nov; 56(11):1690-6. PubMed ID: 26338896
[TBL] [Abstract][Full Text] [Related]
25. Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma.
Sakaguchi T; Yoshino H; Sugita S; Miyamoto K; Yonemori M; Osako Y; Meguro-Horike M; Horike SI; Nakagawa M; Enokida H
Oncotarget; 2018 May; 9(33):23003-23017. PubMed ID: 29796168
[TBL] [Abstract][Full Text] [Related]
26. Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells.
Kim KI; Kang JH; Chung JK; Lee YJ; Jeong JM; Lee DS; Lee MC
J Nucl Med; 2007 Sep; 48(9):1553-61. PubMed ID: 17704247
[TBL] [Abstract][Full Text] [Related]
27. Expression of miR-100 and RBSP3 in FTC-133 cells after exposure to 131I.
Zhang S; Deng B; Zhang Y; Jiang N
Nucl Med Commun; 2014 Sep; 35(9):932-8. PubMed ID: 24785011
[TBL] [Abstract][Full Text] [Related]
28. Reinduction of cell differentiation and 131I uptake in a poorly differentiated thyroid tumor in response to the reverse transcriptase (RT) inhibitor nevirapine.
Modoni S; Landriscina M; Fabiano A; Fersini A; Urbano N; Ambrosi A; Cignarelli M
Cancer Biother Radiopharm; 2007 Apr; 22(2):289-95. PubMed ID: 17600478
[TBL] [Abstract][Full Text] [Related]
29. All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes.
Elisei R; Vivaldi A; Agate L; Ciampi R; Molinaro E; Piampiani P; Romei C; Faviana P; Basolo F; Miccoli P; Capodanno A; Collecchi P; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2005 Apr; 90(4):2403-11. PubMed ID: 15623821
[TBL] [Abstract][Full Text] [Related]
30. Targeting bromodomain-containing protein 4 (BRD4) benefits rheumatoid arthritis.
Zhang QG; Qian J; Zhu YC
Immunol Lett; 2015 Aug; 166(2):103-8. PubMed ID: 26093279
[TBL] [Abstract][Full Text] [Related]
31. Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor.
Zarnegar R; Brunaud L; Kanauchi H; Wong M; Fung M; Ginzinger D; Duh QY; Clark OH
Surgery; 2002 Dec; 132(6):984-90; discussion 990. PubMed ID: 12490845
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase inhibition affects sodium iodide symporter expression and induces 131I cytotoxicity in anaplastic thyroid cancer cells.
Pugliese M; Fortunati N; Germano A; Asioli S; Marano F; Palestini N; Frairia R; Boccuzzi G; Catalano MG
Thyroid; 2013 Jul; 23(7):838-46. PubMed ID: 23531031
[TBL] [Abstract][Full Text] [Related]
33. Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.
Bihani T; Ezell SA; Ladd B; Grosskurth SE; Mazzola AM; Pietras M; Reimer C; Zinda M; Fawell S; D'Cruz CM
Oncotarget; 2015 Feb; 6(4):2407-20. PubMed ID: 25537515
[TBL] [Abstract][Full Text] [Related]
34. JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer.
Qiu H; Jackson AL; Kilgore JE; Zhong Y; Chan LL; Gehrig PA; Zhou C; Bae-Jump VL
Oncotarget; 2015 Mar; 6(9):6915-30. PubMed ID: 25762632
[TBL] [Abstract][Full Text] [Related]
35. Iodide uptake and experimental 131I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I- symporter gene.
Shimura H; Haraguchi K; Miyazaki A; Endo T; Onaya T
Endocrinology; 1997 Oct; 138(10):4493-6. PubMed ID: 9322970
[TBL] [Abstract][Full Text] [Related]
36. Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors.
Puppin C; D'Aurizio F; D'Elia AV; Cesaratto L; Tell G; Russo D; Filetti S; Ferretti E; Tosi E; Mattei T; Pianta A; Pellizzari L; Damante G
Endocrinology; 2005 Sep; 146(9):3967-74. PubMed ID: 15919754
[TBL] [Abstract][Full Text] [Related]
37. Bromodomain‑containing protein 4 is critical for the antiproliferative and pro‑apoptotic effects of gambogic acid in anaplastic thyroid cancer.
Wang Y; Wang W; Sun H
Int J Mol Med; 2018 Jul; 42(1):161-170. PubMed ID: 29717765
[TBL] [Abstract][Full Text] [Related]
38. Recombinant human TSH increases uptake and effective half-life of radioiodine in thyroid hormone secreting metastases of follicular thyroid cancer.
Schneider C; Dietlein M; Eschner W; Schmidt M; Kahraman D; Kobe C
Exp Clin Endocrinol Diabetes; 2012 Mar; 120(3):160-3. PubMed ID: 22328109
[TBL] [Abstract][Full Text] [Related]
39. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression.
Cengic N; Baker CH; Schütz M; Göke B; Morris JC; Spitzweg C
J Clin Endocrinol Metab; 2005 Aug; 90(8):4457-64. PubMed ID: 15941870
[TBL] [Abstract][Full Text] [Related]
40. CG13250, a novel bromodomain inhibitor, suppresses proliferation of multiple myeloma cells in an orthotopic mouse model.
Imayoshi N; Yoshioka M; Chauhan J; Nakata S; Toda Y; Fletcher S; Strovel JW; Takata K; Ashihara E
Biochem Biophys Res Commun; 2017 Mar; 484(2):262-268. PubMed ID: 28115161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
